ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CRSP CRISPR Therapeutics AG

55,03
1,22 (2,27%)
Zuletzt aktualisiert: 20:32:47
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
1,22 2,27% 55,03 20:32:47
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
54,48 53,985 55,34 53,81
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.4.202422:30GLOBECRISPR Therapeutics to Present Oral Presentation at the..
03.4.202414:00GLOBECRISPR Therapeutics to Present at the Annual Needham Virtual..
01.4.202414:00GLOBECRISPR Therapeutics to Present at the American Society of..
13.3.202413:30GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
21.2.202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202413:50EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21.2.202413:45EDGAR2Form 8-K - Current report
21.2.202413:30GLOBECRISPR Therapeutics Provides Business Update and Reports..
16.2.202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:30EDGAR2Form 144 - Report of proposed sale of securities
15.2.202414:30GLOBECRISPR Therapeutics to Present at the Citi 2024 Virtual..
13.2.202414:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13.2.202414:30GLOBECRISPR Therapeutics Announces $280 Million Registered Direct..
13.2.202412:30EDGAR2Form 8-K - Current report
13.2.202408:30GLOBEEuropean Commission Approves First CRISPR/Cas9 Gene-Edited..
31.1.202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202422:08EDGAR2Form 144 - Report of proposed sale of securities
29.1.202422:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18.1.202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.1.202423:00EDGAR2Form 144 - Report of proposed sale of securities
16.1.202422:11EDGAR2Form 8-K - Current report
16.1.202422:01GLOBECRISPR Therapeutics Announces U.S. Food and Drug..
10.1.202417:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.1.202413:00GLOBECRISPR Therapeutics Highlights Strategic Priorities and 2024..
03.1.202414:30GLOBECRISPR Therapeutics to Present at the 42nd Annual J.P...
19.12.202322:23EDGAR2Form 8-K - Current report
15.12.202314:58EDGAR2Form 8-K - Current report
13.12.202315:22EDGAR2Form 8-K - Current report
08.12.202322:11DJNBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
08.12.202319:16EDGAR2Form 8-K - Current report
08.12.202318:52BWVertex and CRISPR Therapeutics Announce US FDA Approval of..
08.12.202317:46DJNCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in..
04.12.202322:26EDGAR2Form 8-K - Current report
04.12.202322:15GLOBECRISPR Therapeutics Announces Updates to Immuno-Oncology..
16.11.202313:21EDGAR2Form 8-K - Current report
16.11.202307:45BW Vertex and CRISPR Therapeutics Announce Authorization of..
06.11.202322:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202322:33EDGAR2Form 8-K - Current report
06.11.202322:15GLOBECRISPR Therapeutics Provides Business Update and Reports..
06.11.202311:01GLOBECRISPR Therapeutics Announces Preclinical Data at the..
01.11.202311:29DJNCrispr Therapeutics Shares Rally Premarket After Favorable..
31.10.202322:53GLOBECRISPR Therapeutics Announces Completion of FDA Advisory..
31.10.202312:05GLOBECRISPR Therapeutics Trading Halted Today; FDA Advisory..
17.10.202323:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.10.202323:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.10.202323:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.10.202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.10.202314:00GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
27.9.202315:01GLOBECRISPR Therapeutics to Present at the Society for..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock